Evidence map›Paper›PMID 30719261›Full record

ArticleRare tumors2019

Soft tissue leiomyosarcoma-diagnostics, management, and prognosis: Data of the registry cancer of the center of Tunisia.

Sarra Mestiri, Mohamed Amine Elghali, Rym Bourigua, Nihed Abdessayed, Salsabil Nasri, Ben Abdallah Amine, Nabiha Missaoui, Mahmoud Ben Maitig, Sihem Hmissa, Badreddine Sriha and 1 more

Abstract read
In one paragraph

Article in Rare tumors, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sarra MestiriDepartment of Pathology, Farhat Hached University Hospital, Sousse, Tunisia.
Mohamed Amine ElghaliDepartment of General Surgery, Farhat Hached University Hospital, Sousse, Tunisia.
Rym BouriguaDepartment of Oncology, Farhat Hached University Hospital, Sousse, Tunisia.
Nihed AbdessayedDepartment of Pathology, Farhat Hached University Hospital, Sousse, Tunisia.
Salsabil NasriDepartment of General Surgery, Farhat Hached University Hospital, Sousse, Tunisia.
Ben Abdallah AmineDepartment of Pathology, Farhat Hached University Hospital, Sousse, Tunisia.
Nabiha MissaouiDepartment of Pathology, Farhat Hached University Hospital, Sousse, Tunisia.
Mahmoud Ben MaitigDepartment of Orthopedy, Hospital Sahloul, Sousse, Tunisia.
Sihem HmissaDepartment of Pathology, Farhat Hached University Hospital, Sousse, Tunisia.
Badreddine SrihaDepartment of Pathology, Farhat Hached University Hospital, Sousse, Tunisia.
Moncef MokniDepartment of Pathology, Farhat Hached University Hospital, Sousse, Tunisia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSoft tissue leiomyosarcomas are rare, accounting for almost 5%-10% of all soft tissue sarcomas; they account for almost 1% of all sarcomas. They are aggressive tumors where location, size, and management require a multidisciplinary approach. Since there are few series published, we here analyze epidemiological pattern, clinical and pathologic features of soft tissue leiomyosarcomas.

methodsWe conducted a retrospective study of 29 consecutive cases of histologically proven soft tissue leiomyosarcoma extracted from the database of the Cancer Registry of the Center of Tunisia and the Department of Pathology of Farhat Hached University Hospital of Sousse of Tunisia, during a 10-year period (from January 1996 to December 2005). Epidemiologic details, clinico-pathological features, and treatment modalities were assessed with focus on patients' 5-year overall survival, tumor relapse, and metastases.

resultsSoft tissue leiomyosarcoma accounted for 17.5% of all soft tissue sarcomas diagnosed at our pathology department. Most of patients were of advanced age (median: 52 years), with extremes ranging from 12 and 87 years. There was a slight male predominance (sex-ratio = 1.07). Tumors were located mostly in the lower limbs (45%). Deep sites as retroperitoneum was found only in two cases. Tumor size was more than 5 cm in 83% of cases (average size = 9.4 cm). Five cases had metastasis on initial staging. For 24 patients, the disease was locally limited at the moment of diagnosis. Palliative chemotherapy was indicated for four patients and surgery was performed for 20 patients. Local recurrence occurred in 11 patients (55% of operated patients) and metastasis in 6 patients. Overall, 5-year survival was about 24%.

conclusionOur study results highlight the scarcity of soft tissue leiomyosarcoma. Unfortunately, unusual tumor sites, disease's advanced stages, and intralesional resection made the prognosis poorer than in other series. Clinical course of soft tissue leiomyosarcoma was highly marked by local recurrence and metastasis.

Indexed as

Leiomyosarcomaprognosissoft tissuetreatment

Identifiers

PMID30719261
PMCPMC6348570

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.